Silver Book Fact

Screening and treatment for diabetic retinopathy in type 2 diabetes patients produces annual savings of 53,986 person-years of sight.

Javitt, Jonathan C., Lloyd Paul Aiello, Yen-Pin Chiang, and S. Greenfield. Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform. Diabetes Care. 1994; 17(8): 909-17. http://care.diabetesjournals.org/cgi/content/abstract/17/8/909

Reference

Title
Preventive Eye Care in People With Diabetes is Cost-Saving to the Federal Government: Implications for health care reform
Publication
Diabetes Care
Publication Date
1994
Authors
Javitt, Jonathan C., Lloyd Paul Aiello, Yen-Pin Chiang, and S. Greenfield
Volume & Issue
Volume 17, Issue 8
Pages
909-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • The ACCORD Eye Study found that combination lipid therapy with a fibrate and statin (compared with statin treatment alone) reduced progression of diabetic retinopathy in type 2 diabetics by around…  
  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Prescription eye drops could delay or prevent half of glaucoma cases in African Americans.  
  • Laser Treatment for DR
    Laser treatment of PDR can reduce the 5-year risk of blindness by 90%, and the risk of visual loss from DME by 50%.